New stem cell autophagy surrogate diagnostic biomarkers in early-stage hepatocellular carcinoma in Egypt: A pilot study

doi:10.4254/wjh.v13.i12.2137

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3575)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-6) series.

Item

Count

PDF

216

WORD

HTML

1589

Figures (1-5)

201

Tables (1-6)

245

Sum=2327

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

406

Download

842

Sum=1248

Dec 27, 2021 (publication date) through Nov 21, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Dec 27, 2021; 13(12): 2137-2149
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2137

Table 1 The ages in the different groups of the study (mean ± SD)

Age	HCC (n = 34)	Chronic liver infection (n = 11)	Control (n = 5)	F¹	P value
	58.88 ± 8.08	56.18 ± 16.26	55.40 ± 22.09	0.34	0.72 NS

¹One-way analysis of variance. HCC: Hepatocellular carcinoma; NS: Non-significant; SD: Standard deviation.

Table 2 Significance of the differences in laboratory data between the three study groups (mean ± SD)

Variable	HCC (n = 34)	Chronic liver infection (n = 11)	Control (n = 5)	F¹	P value
INR	1.37^a± 0.20	1.35^a± 0.30	1.07^b± 0.08	3.93	0.03 S
Serum albumin (g/dL)	2.94 ± 0.42	3.03 ± 0.73	3.40 ± 0.25	1.95	0.15 NS
AST²(IU/L)	50.00^a± 38.00–102.00	23.00^b± 15.00–39.00	15.00^b± 14.00–18.00	16.21	< 0.001 HS
ALT²(IU/L)	40.50^a± 28.00–73.30	22.00 ± 15.00–38.00	10.00^b± 8.00–15.00	12.69	0.002 HS
Total bilirubin²(mg/dL)	1.60^a± 1.10–2.20	1.10 ± 0.50–1.60	0.40^b± 0.30–0.50	14.91	0.001 HS
Direct bilirubin²(mg/dL)	0.70^a± 0.50–1.10	0.30^b± 0.10–0.60	0.10^b± 0.10–0.20	15.84	< 0.001 HS

¹One-way analysis of variance (a, b Post-hoc test).

²Kruskal–Wallis test (median and interquartile range).

^aP < 0.05.

^bP < 0.01.

ALT: Alanine transaminase; AST: Aspartate transaminase; HCC: Hepatocellular carcinoma; HS: Highly significant; INR: International normalized ratio; NS: Non-significant; SD: Standard deviation.

Table 3 Hepatitis virus B and C infections in the three study groups

Variable		HCC (n = 34), (%)	Chronic liver infection (n = 11), (%)	Control (n = 5), (%)	(X²)¹	P value
HCVAb	Positive	30 (88.2)	11 (100.0)	0 (0.0)	18.32 FE	< 0.001 HS
HCVAb	Negative	4 (11.8)	0 (0.0)	5 (100.0)	18.32 FE	< 0.001 HS
HBsAg	Positive	2 (5.9)	0 (0.0)	0 (0.0)	0.78 FE	1.00 NS
HBsAg	Negative	32 (94.1)	11 (100.0)	5 (100.0)	0.78 FE	1.00 NS

¹The chi-square test (FE: Fisher’s exact test). HBsAg: Hepatitis B virus surface antigen; HCC: Hepatocellular carcinoma; HCVAb: Hepatitis C virus antibody; HS: Highly significant; NS: Non-significant.

Table 4 Expression level of hsa-miR-519d-3p, ACTB, RNU6, and SQSTM1 between the three study groups (mean ± SD)

Variable	HCC (n = 34)	Chronic liver infection (n = 11)	Control (n = 5)	F¹	P value
Ct (ACTB)	30.65^a± 4.21	25.82^b± 2.31	27.34^b± 2.00	7.69	0.001 HS
Ct (RNU6)	36.03 ± 2.92	36.36 ± 2.82	38.55 ± 0.96	1.78	0.18 NS
Ct (miR-519d)	30.08^a± 3.00	33.61^b± 2.78	38.05^c± 1.08	20.48	< 0.001 HS
mRNA-SQSTM1	36.14 ± 3.17	34.89 ± 2.30	38.38 ± 1.86	2.48	0.10 NS
DCT (miR-519d)	−5.95^a± 1.98	−2.75^b± 0.89	−0.50^c± 0.40	31.17	< 0.001 HS
DDCT (miR-519d)	−5.59^a± 1.98	−2.39^b± 0.89	−0.14^c± 0.40	31.17	< 0.001 HS
RQ (miR-519d)²	41.94^a± 18.25–139.10	5.98^b± 3.14–8.28	1.17^c± 1.16–1.21	28.46	< 0.001 HS
DCT (SQSTM1)	5.49^a± 1.83	9.07^b± 0.70	11.04^c± 0.58	41.08	< 0.001 HS
DDCT (SQSTM1)	−5.51^a± 1.83	−1.93^b± 0.70	0.04^c± 0.58	41.08	< 0.001 HS
RQ (SQSTM1)²	33.91^a± 14.83–132.51	3.68^b± 2.28–5.50	0.84^c± 0.76–0.99	32.54	< 0.001 HS

¹One-way analysis of variance (a, b post-hoc test).

²Kruskal–Wallis test (median and interquartile range).

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

Ct: Threshold cycle; HS: Highly significant; NS: Non-significant.

Table 5 Alpha-fetoprotein laboratory results in the three subgroups

Variable	HCC (n = 34), median (IQR)	Chronic liver disease (n = 11), median (IQR)	Control (n = 5), median (IQR)		P value
AFP¹(ng/mL) by ELISA	62.60^a(8.20–600.80)	3.50^b(2.50–20.00)	0.70^c(0.50–1.00)	19.17	< 0.001 HS

¹Kruskal–Wallis test (median and interquartile range).

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

AFP: Alpha-fetoprotein; ELISA: Enzyme-linked immunosorbent assay; HCC: Hepatocellular carcinoma; HS: Highly significant; IQR: Interquartile range.

Table 6 Clinical and radiological characteristics of hepatocellular carcinoma lesions.

Variable		mean ± SD
Child–Pugh score		6.76 ± 1.44
		n (%)
Cirrhosis	Cirrhosis	27 (79.4)
Cirrhosis	No cirrhosis	7 (20.6)
BCLC stage	Stage A (early)	31 (91.2)
BCLC stage	Stage D (late)	3 (8.8)
Child–Pugh classification	A	17 (50.0)
	B	14 (41.2)
	C	3 (8.8)
Average tumor size	> 3 cm	3 (8.8)
Average tumor size	< 3 cm	31 (91.2)

BCLC: Barcelona Clinic Liver Cancer; SD: Standard deviation.

Citation: Yosef T, Ibrahim WA, Matboli M, Swilam AA, El-Nakeep S. New stem cell autophagy surrogate diagnostic biomarkers in early-stage hepatocellular carcinoma in Egypt: A pilot study . World J Hepatol 2021; 13(12): 2137-2149
URL: https://www.wjgnet.com/1948-5182/full/v13/i12/2137.htm
DOI: https://dx.doi.org/10.4254/wjh.v13.i12.2137